v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
Apr. 30, 2026
Jul. 31, 2025
CURRENT ASSETS:    
Cash and cash equivalents $ 6,880,221 $ 10,493,808
Short-term investments 15,924,204 7,372,473
Amounts receivable and prepaid expenses 2,588,749 2,060,295
Total current assets 25,393,174 19,926,576
NON-CURRENT ASSETS:    
Equity investment in BC Therapeutics 750,982 524,278
Intangible assets, net 173,072 184,525
Property and equipment, net 348,997 296,819
Long term prepaid expenses 405,085 717,508
Total non-current assets 1,678,136 1,723,130
Total assets 27,071,310 21,649,706
CURRENT LIABILITIES:    
Trade payables 2,174,437 3,283,703
Accrued expenses and other payables 1,416,059 694,285
Total current liabilities 3,590,496 3,977,988
NON-CURRENT LIABILITIES:    
Warrant liability 71,854 337,672
Total non-current liabilities 71,854 337,672
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY:    
Share Capital of no par value – Authorized: unlimited at April 30, 2026 and July 31, 2025; Issued and outstanding: 7,250,487 shares at April 30, 2026 and 1,883,906 July 31, 2025, respectively 117,117,225 101,739,923
Share-based payment reserved 11,202,809 10,316,140
Warrant reserve 30,216,165 17,719,026
Accumulated other comprehensive loss (138,684) (138,684)
Non-controlling interest (649,099) (546,795)
Accumulated deficit (134,339,456) (111,755,564)
Total shareholders’ equity 23,408,960 17,334,046
Total liabilities and shareholders’ equity $ 27,071,310 $ 21,649,706